Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A (2015) The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 10:e0140908

Article  PubMed  PubMed Central  Google Scholar 

Temple JL, Cordero P, Li J, Nguyen V, Oben JA (2016) A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci 17:947

Article  PubMed  PubMed Central  Google Scholar 

Li J, Ha A, Rui F, Zou B, Yang H, Xue Q, Hu X, Xu Y, Henry L, Barakat M (2022) Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000–2021. Aliment Pharmacol Ther 56:396–406

Article  CAS  PubMed  Google Scholar 

Ma J, Wang Z, Song Y, Hu P, Zhang B (2010) BMI percentile curves for Chinese children aged 7–18 years, in comparison with the WHO and the US Centers for Disease Control and Prevention references. Public Health Nutr 13(12):1990–1996

Article  PubMed  Google Scholar 

Friesen CS, Hosey-Cojocari C, Chan SS, Csanaky IL, Wagner JB, Sweeney BR, Friesen A, Fraser JD, Shakhnovich V (2021) Efficacy of weight reduction on pediatric nonalcoholic fatty liver disease: opportunities to improve treatment outcomes through pharmacotherapy. Front Endocrinol (Lausanne) 12:663351

Article  PubMed  Google Scholar 

Harrison S, Fincke C, Helinski D, Torgerson S, Hayashi P (2004) A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 20:623–628

Article  CAS  PubMed  Google Scholar 

Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, Wang W, Feng S, Zhong B (2019) Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Ther Adv Gastroenterol 12:1756284819879047

Article  Google Scholar 

Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U (2017) Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Therap Clin Risk Manag 139–149

Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:80–86

Article  CAS  PubMed  Google Scholar 

Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N (2007) Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 52:2512–2519

Article  PubMed  Google Scholar 

Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB (2003) The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 12:189–192

PubMed  Google Scholar 

Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP (2017) The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 10:1225–1237

Article  CAS  PubMed  Google Scholar 

McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA (2002) Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 10:642–650

Article  CAS  PubMed  Google Scholar 

Chanoine J-P, Hampl S, Jensen C, Boldrin M, Hauptman J (2005) Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293:2873–2883

Article  CAS  PubMed  Google Scholar 

Halpern B, Halpern A (2015) Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf 14:305–315

Article  CAS  PubMed  Google Scholar 

Baranowski T, Taveras EM (2018) Childhood obesity prevention: changing the focus. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA, pp 1–3

Hallal PC, Victora CG (2004) Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc 36:556

Article  PubMed  Google Scholar 

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

Article  CAS  PubMed  Google Scholar 

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P (2008) Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48:119–128

Article  CAS  PubMed  Google Scholar 

Louthan MV, Theriot JA, Zimmerman E, Stutts JT, McClain CJ (2005) Decreased prevalence of nonalcoholic fatty liver disease in black obese children. J Pediatr Gastroenterol Nutr 41:426–429

Article  PubMed  Google Scholar 

Seth A, Orkin S, Yodoshi T, Liu C, Fei L, Hardy J, Trout AT, Arce Clachar AC, Bramlage K, Xanthakos S (2020) Severe obesity is associated with liver disease severity in pediatric non-alcoholic fatty liver disease. Pediatr Obes 15:e12581

Article  PubMed  Google Scholar 

Wald AB, Uli NK (2009) Pharmacotherapy in pediatric obesity: current agents and future directions. Rev Endocr Metab Disord 10:205–214

Article  CAS  PubMed  Google Scholar 

Yu CC, Li AM, Chan KO, Chook P, Kam JT, Au CT, So RC, Sung RY, McManus AM (2013) Orlistat improves endothelial function in obese adolescents: a randomised trial. J Paediatr Child Health 49:969–975

Article  PubMed  Google Scholar 

Maahs D, De Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS (2006) Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 12:18–28

Article  PubMed  Google Scholar 

Wang C, Pai AK, Putra J (2022) Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. J Clin Pathol 75:443–451

Article  CAS  PubMed  Google Scholar 

Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M (2021) Protective and therapeutic effects of orlistat on metabolic syndrome and oxidative stress in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) in rats: role on Nrf2 activation. Veterinary sciences 8:274

Article  PubMed  PubMed Central  Google Scholar 

Esmail VAW, Mohammed MO, Al-Nimer MS (2021) Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology 22:1–5

Article  PubMed  Google Scholar 

Bush H, Golabi P, Younossi ZM (2017) Pediatric non-alcoholic fatty liver disease. Children 4:48

Article  PubMed  PubMed Central  Google Scholar 

Al-Tahami BAM, Ab AA-SI, Sanip Z, Yusoff Z, Shihabudin TMT, Singh TSP, Rasool AHG (2017) Metabolic and inflammatory changes with orlistat and sibutramine treatment in obese Malaysian subjects. J Nippon Med Sch 84:125–132

Article  PubMed  Google Scholar 

Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Investig 108:1875–1881

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ke J, An Y, Cao B, Lang J, Wu N, Zhao D (2020) Orlistat-induced gut microbiota modification in obese mice. Evidence-Based Complementary and Alternative Medicine (eCAM)

Nikniaz Z, Nikniaz L, Farhangi MA, Mehralizadeh H, Salekzamani S (2023) Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis. BMC Endocr Disord 23:142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahin M, Tanaci N, Yucel M, Tutuncu NB, Guvener N (2007) The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. Clin Endocrinol 67:346–350

Article  CAS  Google Scholar 

Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Investig 113:1582–1588

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK (1999) Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J Clin Investig 104:1087–1096

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim DW, Park C, Yoon HM, Jung AY, Lee JS, Jung SC, Cho YA (2019) Technical performance of shear wave elastography for measuring liver stiffness in pediatric and adolescent patients: a systematic review and meta-analysis. Eur Radiol 29:2560–2572

Article  PubMed  Google Scholar 

Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L, Castellano A, de Ville de Goyet J (2014) Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 9:e99–e102

Article  CAS  PubMed  Google Scholar 

Stefan N, Kantartzis K, Häring H-U (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960

Article  CAS  PubMed  Google Scholar 

Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55:S9–S15

Article  CAS  PubMed